Further validation of the efficacy of mesenchymal stem cell infusions for reducing mortality in COVID-19 patients with ARDS. Academic Article

abstract

• Recent double-blind, randomized, controlled trials reported that human umbilical cord-derived mesenchymal stem cell (MSC) infusions in COVID-19 patients with acute respiratory distress syndrome (ARDS) could diminish cytokine storm and lung damage. While these outcomes are significant, additional phase II/III trials are required to validate the efficacy of MSCs to improve the survival of COVID-19 patients with ARDS. Future studies also need to assess the efficacy of MSCs to prevent long COVID.

authors

• Shetty, Ashok

published proceedings

• NPJ Regen Med

altmetric score

• 10.072

author list (cited authors)

• Shetty, A. K., Shetty, P. A., Zanirati, G., & Jin, K.

citation count

• 3

complete list of authors

• Shetty, Ashok K||Shetty, Padmashri A||Zanirati, Gabriele||Jin, Kunlin

publication date

• January 2021

publisher

• Springer Nature  Publisher

published in

• npj Regenerative Medicine  Journal

keywords

• 3 Good Health And Well Being
• Acute Respiratory Distress Syndrome
• Clinical Research
• Clinical Trials And Supportive Activities
• Lung
• Prevention
• Rare Diseases
• Regenerative Medicine
• Respiratory
• Stem Cell Research
• Stem Cell Research - Nonembryonic - Human
• Stem Cell Research - Umbilical Cord Blood/ Placenta
• Transplantation

Digital Object Identifier (DOI)

• 10.1038/s41536-021-00161-z

start page

• 53

volume

• 6

issue

• 1

URL

• http://dx.doi.org/10.1038/s41536-021-00161-z

user-defined tag

• 3 Good Health and Well-Being